Telehealth GLP-1 prescriptions
A GLP-1 telehealth service, publicly launched in September 2026, that prescribes compounded semaglutide and tirzepatide after an online clinician review. Both drugs are offered as a weekly injection or a daily oral tablet.
We may earn a commission if you buy through the links to Zenbody on this page, at no extra cost to you. That does not change how we grade or rank it, and Zenbody did not write or approve this review.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Prescription-only compounded semaglutide and tirzepatide, dispensed after an online clinician review.
Everything here is a prescription service that starts with a licensed clinician's review of your own health information. Compounded medications are made by a pharmacy against a prescription and are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality. This entry describes what the brand offers and what we could check. It is not medical advice and not a recommendation to use it.
Every telehealth brand we rank gets the same five checks, read from its public pages on September 24, 2026. "Not met" means we did not find it, or the terms say otherwise, on the pages we could read. Price and commission play no part.
Shows 'from' starting-dose prices and says pricing is flat after month one, without stating the flat amount.
Its terms name Remedora Inc., PC as the affiliated medical group.
Its terms name Rush Pharmacy of Oviedo, Florida.
Terms say fees are not refundable in whole or in part.
No warning letter under this name in FDA's public database on September 24, 2026.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
The homepage quotes the STEP-1 and SURMOUNT-1 trial results with DOIs and then states, in its own words, that those results do not establish the effectiveness of Zenbody's compounded formulations. We read that on the page. It is a more careful framing than most brands in this category use.
Where the vendor states thisThe homepage shows 'From $149/mo' next to a '40% off your first month' promotion. The tirzepatide page shows 'from $179 per month' for the injection and 'from $299' for the tablet as starting-dose prices, with flat monthly pricing after month one. We confirmed this ourselves.
Where the vendor states thisStated for both drugs on the homepage. We confirmed this ourselves.
Where the vendor states thisFDA does not review compounded drugs for safety, effectiveness or quality before they are sold. In 2026 FDA warned 30 telehealth companies over claims implying sameness with approved drugs, and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, so the legal footing of this category can change.
Press releases dated September 12, 2026 describe the platform as newly launched. There is little independent history on service quality, cancellations or refunds yet.
'From $149' and 'from $179' are starting-dose prices, and the site says pricing is flat after month one without stating the flat amount.
No. Zenbody prescribes compounded semaglutide and tirzepatide. Compounded drugs are made by a pharmacy against a prescription and FDA does not review them for safety, effectiveness or quality.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 24, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
